Tepotinib

Healio spoke with Melina Elpi Marmarelis, MD, about data from the INSIGHT 2 trial presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.

CHICAGO — Long-term follow up shows that response to tepotinib remains robust in patients with MET exon-14 skipping non-small cell lung cancer, according to research presented at ASCO Annual Meeting.

Female breast cancer has superseded lung cancer as the world’s most common cancer diagnosis, according to a recent report. It was the top story in hematology/oncology last week.

The FDA granted accelerated approval to tepotinib for treatment of certain patients with metastatic non-small cell lung cancer.